QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Corbus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRBP)

$6.11
-0.07 (-1.13%)
(As of 12/5/2023 ET)
Compare
Today's Range
$5.92
$6.25
50-Day Range
$3.16
$6.74
52-Week Range
$2.11
$13.17
Volume
11,246 shs
Average Volume
142,398 shs
Market Capitalization
$27.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.6% Upside
$12.50 Price Target
Short Interest
Bearish
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.17mentions of Corbus Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.00) to ($6.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

374th out of 948 stocks

Pharmaceutical Preparations Industry

159th out of 423 stocks


CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Corbus Pharmaceuticals Holding (0SZI)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
CRBP - Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals (NASDAQ: CRBP)
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
33
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$22.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+105.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$7.91 per share

Miscellaneous

Free Float
4,123,000
Market Cap
$26.92 million
Optionable
Optionable
Beta
2.35

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 48)
    CEO & Director
    Comp: $890.67k
  • Mr. Sean F. Moran CPA (Age 65)
    M.B.A., Chief Financial Officer
    Comp: $579.05k
  • Dr. Rachael Brake Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $552.22k
  • Ted Jenkins
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Lindsey Smith
    Head of Corporate Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of Human Resources














CRBP Stock Analysis - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRBP shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 1-year price objectives for Corbus Pharmaceuticals' shares. Their CRBP share price targets range from $3.00 to $22.00. On average, they predict the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 104.6% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of 2023. Since then, CRBP shares have increased by 5,429.4% and is now trading at $6.11.
View the best growth stocks for 2023 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the consensus estimate of ($2.06) by $0.21.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRBP) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -